Literature DB >> 9783914

Role of TNF receptor 1 in protein turnover during cancer cachexia using gene knockout mice.

M Llovera1, C García-Martínez, J López-Soriano, N Carbó, N Agell, F J López-Soriano, J M Argiles.   

Abstract

The implantation of the Lewis lung carcinoma (a fast-growing mouse tumour that induces cachexia) to both wild-type and gene-deficient mice for the TNF-alpha receptor type I protein (Tnfr1 degree/Tnfr1 degree), resulted in a considerable loss of carcass weight in both groups. However, while in the wild-type mice there was a loss of both fat and muscle, in the gene-knockout mice muscle wastage was not affected to the same extent. In both groups, tumour burden resulted in significant increases in circulating TNF-alpha, a cytokine which, as we have previously demonstrated, can induce protein breakdown in skeletal muscle. Muscle wastage in wild-type mice was accompanied by an increase in the fractional rate of protein degradation, while no changes were observed in protein synthesis. The result is a decreased rate of protein accumulation that accounts for the muscle weight loss observed as a result of tumour burden. In contrast, gene knockout mice did not have significantly lower rates of protein accumulation as a result of tumour implantation. The increase in protein degradation in the tumour-bearing wild mice was accompanied by an enhanced expression of both ubiquitin and proteasome subunit genes, all of them related to the activation of the ATP-dependent proteolytic system in skeletal muscle. Tumour-bearing gene-deficient mice did not show any increase in gene expression. It is concluded that TNF-alpha (alone or in combination with other cytokines) is responsible for the activation of protein breakdown in skeletal muscle of tumour-bearing mice.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9783914     DOI: 10.1016/s0303-7207(98)00105-1

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  30 in total

1.  Lewis lung carcinoma regulation of mechanical stretch-induced protein synthesis in cultured myotubes.

Authors:  Song Gao; James A Carson
Journal:  Am J Physiol Cell Physiol       Date:  2015-10-21       Impact factor: 4.249

Review 2.  The cancer anorexia/weight loss syndrome: therapeutic challenges.

Authors:  Karin F Giordano; Aminah Jatoi
Journal:  Curr Oncol Rep       Date:  2005-07       Impact factor: 5.075

Review 3.  Role of nuclear factor κB-mediated inflammatory pathways in cancer-related symptoms and their regulation by nutritional agents.

Authors:  Subash C Gupta; Ji Hye Kim; Ramaswamy Kannappan; Simone Reuter; Patrick M Dougherty; Bharat B Aggarwal
Journal:  Exp Biol Med (Maywood)       Date:  2011-05-12

4.  Formoterol and cancer muscle wasting in rats: Effects on muscle force and total physical activity.

Authors:  Sílvia Busquets; Míriam Toledo; Sònia Sirisi; Marcel Orpí; Roberto Serpe; Joana Coutinho; Raquel Martínez; Josep M Argilés; Francisco J López-Soriano
Journal:  Exp Ther Med       Date:  2011-04-28       Impact factor: 2.447

Review 5.  The Sick and the Weak: Neuropathies/Myopathies in the Critically Ill.

Authors:  O Friedrich; M B Reid; G Van den Berghe; I Vanhorebeek; G Hermans; M M Rich; L Larsson
Journal:  Physiol Rev       Date:  2015-07       Impact factor: 37.312

6.  Mechanisms of Cachexia in Chronic Disease States.

Authors:  Tadashi Yoshida; Patrice Delafontaine
Journal:  Am J Med Sci       Date:  2015-10       Impact factor: 2.378

7.  Doxorubicin acts through tumor necrosis factor receptor subtype 1 to cause dysfunction of murine skeletal muscle.

Authors:  Laura A A Gilliam; Leonardo F Ferreira; Joseph D Bruton; Jennifer S Moylan; Håkan Westerblad; Daret K St Clair; Michael B Reid
Journal:  J Appl Physiol (1985)       Date:  2009-09-24

8.  Formoterol treatment downregulates the myostatin system in skeletal muscle of cachectic tumour-bearing rats.

Authors:  Sílvia Busquets; Míriam Toledo; Enrica Marmonti; Marcel Orpí; Eva Capdevila; Angelica Betancourt; Francisco J López-Soriano; Josep M Argilés
Journal:  Oncol Lett       Date:  2011-10-13       Impact factor: 2.967

9.  A pilot study on safety and pharmacokinetics of infliximab for the cancer anorexia/weight loss syndrome in non-small-cell lung cancer patients.

Authors:  Aminah Jatoi; James R Jett; Jeff Sloan; Paul Novotny; Joyce Ford; Uma Prabhakar; Charles L Loprinzi
Journal:  Support Care Cancer       Date:  2004-09-15       Impact factor: 3.603

10.  Cancer cachexia is regulated by selective targeting of skeletal muscle gene products.

Authors:  Swarnali Acharyya; Katherine J Ladner; Lori L Nelsen; Jeffrey Damrauer; Peter J Reiser; Steven Swoap; Denis C Guttridge
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.